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Protein kinases of the receptor interacting protein (RIP) family collaborate with death receptor 
proteins to regulate cell death. Recent studies (Cho et al., 2009; He et al., 2009; Zhang et al., 2009) 
reveal that the RIP3 kinase functions with RIP1 at the crossroads of apoptosis, necroptosis, and 
cell survival.A cell can die in many different ways, but caspase-dependent 
apoptosis is thought to be the predominant pathway for cell 
death. However, in the absence of caspase activation, a pro-
cess of programmed necrosis, called necroptosis, prevails. Lit-
tle is known about the proteins involved in necroptotic signal-
ing, but recent reports indicate that it shares some regulatory 
mechanisms with apoptosis. Indeed, the kinase receptor inter-
acting protein 1 (RIP1) has been implicated in the regulation of 
apoptosis (Wang et al., 2008) as well as necroptosis (Degterev 
et al., 2008; Holler et al., 2000). Findings recently reported in 
Cell (Cho et al., 2009; He et al., 2009) and Science (Zhang et al., 
2009) now make an important contribution to the understand-
ing of necroptotic signaling by describing an essential role for 
the RIP3 kinase in the decision between tumor necrosis factor 
(TNF)-induced necroptosis and survival when apoptotic sig-
naling is blocked.
RIP1 in Life and Death
RIP serine/threonine kinase family members are essential sen-
sors of cellular stress. They share a homologous N-terminal 
kinase domain but have different recruitment domains. The 
death domain of the RIP1 kinase binds to death receptors such 
as TNF receptor 1 (TNFR1), Fas, tumor necrosis factor-related 
apoptosis-inducing ligand receptor 1 (TRAILR1), and TRAILR2. 
It also associates with death domain-containing adaptor pro-
teins, such as TNF-receptor-associated death domain (TRADD) 
and Fas-associated death domain (FADD), that are required for 
caspase-8 activation and apoptosis (Schutze et al., 2008; Wil-
son et al., 2009). The intermediate domain of RIP1 contains a 
RIP homotypic interaction motif that enables it to interact with 
RIP3. Consistent with a role for RIP1 in regulating apoptosis, 
mice lacking RIP1 display extensive apoptosis and die at 1 to 
3 days of age (Kelliher et al., 1998). Moreover, cultured cells 
lacking RIP1 are highly sensitive to TNF-induced cell death, 
possibly because they are unable to activate the prosurvival 
transcription factor NF-κB.
In most cell types, the death receptors TNFR1, Fas, and 
TRAILR mediate apoptosis. Activated TNFR1 triggers the 
polyubiquitination of RIP1 by inhibitors of apoptosis proteins (IAPs) cIAP1 and cIAP2 (Mahoney et al., 2008; Varfolom-
eev et al., 2008). The ubiquitination state of RIP1 determines 
whether it functions as a prosurvival scaffold molecule or a 
kinase that promotes cell death. RIP1 decorated with ubiquitin 
chains linked through lysine 63 (K63) of ubiquitin promotes the 
downstream activation of mitogen-activated protein kinases 
(MAPKs) and NF-κB (Figure 1, complex I), which govern the 
expression of prosurvival genes. The ubiquitin chains can be 
removed by the deubiquitinases cylindromatosis (CYLD) and 
A20 (Wilson et al., 2009). When K63 ubiquitination of RIP1 and 
TNF-induced NF-κB activation are reduced through cIAP1 and 
cIAP2 depletion by genetic ablation or Smac mimetics (small 
molecules that induce IAP degradation) (Mahoney et al., 2008; 
Varfolomeev et al., 2008), RIP1 switches its function to that of 
promoting cell death (Wang et al., 2008) (Figure 1).
When apoptotic cell death is blocked by pan-caspase 
inhibitors such as benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluo-
romethylketone (zVAD), the cell uses necroptosis as an alter-
native cell death pathway (Festjens et al., 2007; Degterev et 
al., 2008; Hitomi et al., 2008). RIP1 kinase activity is crucial for 
this alternative pathway induced by the FasL, TNF, and TRAIL 
death receptors (Holler et al., 2000). Indeed, necrostatin-1, 
an allosteric RIP1 kinase inhibitor, inhibits death receptor-
induced necroptosis in different cellular models, indicating 
that necroptotic signaling is mediated by a common mecha-
nism (Degterev et al., 2008). Knockdown of CYLD expression 
inhibits TNF-induced necroptosis in cultured human Jurkat 
cells that lack the apoptotic factor FADD (Hitomi et al., 2008). 
In the presence of Smac mimetics, unubiquitinated RIP1 forms 
a complex with FADD and caspase-8 independently of the 
TRADD-dependent death-inducing signaling complex (Figure 
1, complex IIB) (Wang et al., 2008). Under these conditions, 
RIP1 kinase activity and CYLD are critical for caspase-8 acti-
vation and apoptosis, suggesting that deubiquitinated RIP1 
promotes the formation of apoptotic or necrotic signaling 
complexes (Hitomi et al., 2008; Wang et al., 2008). However, 
in the absence of Smac mimetics, RIP1 kinase activity is not 
required for death receptor-induced activation of caspase-8 
(Wilson et al., 2009).Cell 138, July 24, 2009 ©2009 Elsevier Inc. 229
Figure 1. The Necrosome, a New Player in 
Death Receptor-Induced Necroptosis
Upon stimulation of the tumor necrosis factor re-
ceptor 1 (TNFR1), TNF-receptor-associated death 
domain (TRADD) provides a scaffold for the as-
sembly of complex I at the plasma membrane by 
binding receptor interacting protein 1 (RIP1), TNF-
receptor-associated factor 2 (TRAF2) or TRAF5, 
and the inhibitor of apoptosis proteins (IAPs) 
cIAP1 and cIAP2. This complex is crucial for ac-
tivating NF-κB and mitogen-activated protein ki-
nase (MAPK) pathways. cIAPs direct the formation 
of polyubiquitin chains linked through lysine 63 
(K63) of ubiquitin on RIP1, thereby allowing it to in-
teract with the TAK1/TAB2/3 (transforming growth 
factor-β-activated kinase 1/TAK1-binding protein 
2/3) complex. K63-linked polyubiquitination on 
TRAF2 can also recruit the TAK1/TAB2/3 complex. 
TAK1 activates the IκB kinase (IKK) complex (com-
posed of IKKα, IKKβ, and NEMO/IKKγ) that in turn 
phosphorylates the NF-κB inhibitor IκB to induce 
its K48 polyubiquitination and proteasomal degra-
dation. Once freed from its inhibitor, NF-κB trans-
locates to the nucleus to activate transcription. In 
a negative feedback loop, NF-κB upregulates A20 
and CYLD, which remove K63-linked polyubiquitin 
chains from RIP1 and abolish its ability to activate 
NF-κB. After internalization of the TNFR1 recep-
tor, secondary cytosolic complexes dependent 
on either TRADD (complex IIA) or RIP1 (complex 
IIB) are formed to initiate apoptosis. Complex IIA 
formation involves Fas-associated death domain 
(FADD)-mediated recruitment and activation of 
caspase-8 for RIP1 and RIP3 cleavage. Complex 
IIB is formed in the presence of Smac mimet-
ics and acts independently of TRADD through a 
RIP1-FADD scaffold to activate caspase-8 in a 
RIP1 kinase-dependent way. It is assumed that 
these secondary complexes primarily contain 
the  unubiquitinated form of RIP1 (generated by 
CYLD or A20 deubiquitination activity). Smac mimetics facilitate cIAP autoubiquitination and proteasomal degradation, thereby promoting the accumulation of 
unubiquitinated RIP1 that can be incorporated into complex IIB. When apoptosis is blocked by experimental (e.g., zVAD treatment) or physiological (e.g., viral 
proteins) conditions, RIP1 and RIP3 assemble a complex containing FADD and caspase-8 (TRADD may also be a component of this complex). Interdependent 
phosphorylation of RIP1 and RIP3 activates necroptotic signaling. RIP3 increases the activities of glycogen phosphorylase, glutamate ammonia ligase, and 
glutamate dehydrogenase 1. This stimulates the production of reactive oxygen species (ROS) due to increased oxidative phosphorylation. In some cells, ROS 
production as a consequence of RIP3 signaling is required for necroptosis.RIP3, a Molecular Switch for Necroptosis?
Many cultured cell lines are protected against TNF-induced 
apoptosis by zVAD treatment, whereas others will undergo 
TNF-induced necroptosis when caspases are inhibited by the 
drug (Festjens et al., 2007). In addition to RIP1, RIP3 kinase 
activity has been implicated in this caspase-independent 
mode of cell death (Feng et al., 2007). However, although 
ectopic expression of RIP3 induces apoptosis, mice lacking 
RIP3 do not exhibit defects in development, NF-κB activation, 
or apoptosis (Newton et al., 2004). From the work of Cho et 
al. (2009), He et al. (2009), and Zhang et al. (2009), it is now 
clear that the expression of RIP3 renders cells permissive to 
necroptosis upon TNF treatment. Zhang et al. show through 
microarray analysis that RIP3 is not expressed in A-type NIH 
3T3 cells protected from TNF-induced apoptosis in the pres-
ence of zVAD, whereas it is present in N-type NIH 3T3 cells 
that show enhanced TNF-induced necroptosis in the presence 
of zVAD (Zhang et al., 2009). Knockdown of RIP3 expression in 
the N-type cells prevents necroptosis in the presence of zVAD. 
Cho et al. and He et al. also demonstrate that the kinase activ-
ity and RIP homotypic interaction motif of RIP3 are required for 
necroptotic signaling. Together, these data implicate RIP3 as 230 Cell 138, July 24, 2009 ©2009 Elsevier Inc.a key switch between TNF-induced necroptosis and survival 
and suggest that the complex containing RIP3 could function 
as a “necrosome” distinct from other complexes that induce 
apoptosis or NF-κB activation.
He and colleagues further implicate both RIP1 and RIP3 as 
essential mediators of TNF-induced necroptosis in cultured 
mouse L929 cells, macrophages in the presence of zVAD, and 
cultured human HT-29 cells in the presence of Smac mimetic 
and zVAD. In cultured cell lines where RIP3 is not expressed, 
a combination treatment of TNF and Smac mimetic results 
in apoptosis (which can be inhibited by zVAD) and does not 
induce a switch to necroptosis. Examining FADD-deficient 
cultured human Jurkat cells, Cho and colleagues identify 
RIP1 and RIP3 among 10 kinases that are required for TNF-
induced necroptosis. Although they only address the involve-
ment in necroptosis of the RIP kinases, several of the other 
identified kinases, such as TAO kinase 3 and protein kinase 
N1, are known to be involved in MAPK signaling or to interact 
with components of the TNF signaling pathway. For example, 
knockdown of the membrane-associated tyrosine/threonine 
kinase 1, which interacts with the antiapoptotic protein Bcl-2, 
protects FADD-deficient Jurkat cells against TNF-induced 
necroptosis (Cho et al., 2009). Intriguingly, Bcl-2 modifying fac-
tor (Bmf), a proapoptotic Bcl-2 protein family member, is also 
required for death receptor-induced necroptosis (Hitomi et al., 
2008), suggesting that Bcl-2 protein family members function 
in necroptosis as well as apoptosis.
Although RIP3 is not a component of the TNFR1-induced 
complex I (Cho et al., 2009; He et al., 2009), it associates with 
TRADD-dependent complex IIA or, in the presence of Smac 
mimetics, with RIP1-dependent complex IIB (Figure 1) (Cho et 
al., 2009; He et al., 2009). It is not known whether RIP3 and 
RIP1 form heterodimers within these complexes or interact as 
homodimers. RIP3 is likely activated and autophosphorylated 
at serine 199 within either complex IIA or -B (He et al., 2009), 
but the sequence of events for activation is not yet clear. In 
vivo, phosphorylation of RIP1 and RIP3 is clearly mutually 
dependent (Cho et al., 2009; He et al., 2009). Similar to the 
recruitment of RIP1 and RIP3 to FADD, the interaction between 
RIP1 and RIP3 is abolished by the RIP1 kinase inhibitor necro-
statin-1 (Cho et al., 2009), indicating that the kinase activity 
of RIP1 is also required for stable RIP1 and RIP3 association. 
Necrostatin-1 also abolishes necroptosis-specific RIP3 phos-
phorylation. However, RIP1 does not phosphorylate RIP3 in 
vitro, whereas RIP3 weakly phosphorylates RIP1 (Cho et al., 
2009). Taken together, these observations suggest the exis-
tence of a phosphorylation-dependent regulatory loop that 
involves RIP1, RIP3, and an unknown kinase (Figure 1).
Cho and colleagues show that FADD is required for RIP3 
recruitment and activation in TNF-treated Jurkat cells. How-
ever, it is not clear how to reconcile these observations with 
the fact that FADD-deficient Jurkat cells treated with TNF can 
undergo necroptosis in a RIP1- and RIP3-dependent man-
ner (Cho et al., 2009; Hitomi et al., 2008). Additionally, RIP1 
phosphorylation still occurs in TNF-treated FADD-deficient 
Jurkat cells in the presence of the RIP1 kinase inhibitor necro-
statin (Cho et al., 2009). This implies that RIP1 and RIP3 can 
be activated in the absence of FADD, possibly as components 
of TRADD-containing complex IIA (Figure 1) (Pobezinskaya et 
al., 2008). However, it has not yet been formally proven that 
TRADD is present in complex IIA when cells are treated with 
caspase inhibitors.
Cho et al. show that RIP1 in complex IIA is cleaved during 
apoptosis in a manner that can be inhibited by zVAD. Cleavage 
of RIP1 under apoptotic conditions could be a mechanism to 
ensure that the cell undergoes apoptotic death by inactivating 
the protein, thereby preventing RIP1-mediated gene activation 
and necroptosis. It seems likely that RIP3 is similarly cleaved 
in complexes containing active caspase-8 (Feng et al., 2007). 
Cho et al. conclude that although RIP1 cleavage by caspase-8 
at aspartic acid 324 might inactivate the kinase, zVAD likely 
sensitizes cells to necroptosis via regulatory events other than 
preventing RIP cleavage because full-length RIP1 can still be 
detected in complex IIA in the absence of caspase inhibitors. 
In view of its known off-target effects, it is possible that zVAD 
has additional necrosis-sensitizing functions (Festjens et al., 
2007). However, in T cells where limited caspase-8 activa-
tion is required for proliferation, loss of caspase-8 results in 
antigen- or mitogen-activated necroptosis that requires RIP1 
(Ch’en et al., 2008) and likely also RIP3 (Cho et al., 2009). Cas-pase cleavage of RIP3 abolishes its ability to activate caspase-
independent cell death (Feng et al., 2007), supporting the idea 
that zVAD functions by blocking RIP kinase cleavage to allow 
necroptosis to proceed (Zhang et al., 2009). Nonetheless, zVAD 
could also prevent capsase 8 from cleaving as yet unknown 
necroptotic factors; additional work will be required to resolve 
zVAD’s precise mechanism of action.
RIP3 Governs the Cell’s Metabolic State
Reactive oxygen species (ROS) derived from mitochondria are 
required for TNF- and double-strand RNA-induced necropto-
sis in L929 cells (Festjens et al., 2007). Cho et al. and Zhang et 
al. now show that RIP3 is required for TNF-induced ROS pro-
duction during necroptosis in L929 cells, N-type NIH 3T3 cells, 
macrophages, and mouse embryonic fibroblasts. However, 
ROS quenching does not prevent necroptosis in HT-19 cells 
treated with a combination of TNF, Smac mimetic, and zVAD, 
indicating that ROS production is only required for necroptosis 
in some cell types or conditions.
Zhang et al. identify seven metabolic enzymes in the RIP3 
complex immunoprecipitated from N-type NIH 3T3 cells that are 
treated with TNF/zVAD. Of these enzymes, RIP3 directly inter-
acts with glycogen phosphorylase (PYGL), glutamate ammonia 
ligase (GLUL), and glutamate dehydrogenase 1 (GLUD1). RIP 
kinase activity is required to enhance the activities of all three 
enzymes both in vivo and in vitro. PYGL catalyzes the degrada-
tion of glycogen by releasing glucose-1-phosphate and so plays 
a key role in utilizing glycogen reserves as an energy source. 
GLUL is a cytosolic enzyme that catalyzes the condensation 
of glutamate and ammonia to form glutamine, whereas GLUD1 
is found in the mitochondrial matrix and converts glutamate to 
α-ketoglutarate. Both GLUL and GLUD1 are essential for the 
use of glutamate or glutamine as substrates for ATP production 
in oxidative phosphorylation. Importantly, knockdown of PYGL, 
GLUL, or GLUD1 partially inhibits TNF/zVAD-induced ROS lev-
els and necroptosis in N-type NIH 3T3 cells. Because breaking 
down glycogen and using glutamate and glutamine as energy 
substrates increases energy metabolism, the role of RIP3 in 
rendering cells more permissive to TNF-induced necroptosis 
could, at least partly, occur through increasing ROS produc-
tion as a consequence of energy metabolism (Festjens et al., 
2007) (Figure 1). Glutamine metabolism also indirectly feeds 
the Krebs cycle and the subsequent respiratory chain, which 
contributes to ROS production. Indeed, cells that are adapted 
to grow without glutamine and those that are pretreated with 
inhibitors of key enzymes of glutaminolysis or glycolysis show 
decreased TNF-induced ROS production, oxidative stress, and 
necroptosis relative to control cells (Festjens et al., 2007).
Physiological Roles for RIP3-Mediated Necroptosis
Necrostatins have recently been shown to prevent tissue dam-
age in mouse models of cerebral ischemia and myocardial 
infarction, implicating necroptosis in pathological cell death 
(Vandenabeele et al., 2008). This form of cell death may occur 
only when caspase activation is impaired or when caspases 
are inhibited. Notably, viruses often express antiapoptotic pro-
teins that prevent recruitment or activation of caspase-8 in the 
death-inducing complex to prolong cell viability and to facilitate Cell 138, July 24, 2009 ©2009 Elsevier Inc. 231
viral replication. Cho et al. show that when T cells lacking RIP3 
are infected with vaccinia virus expressing the viral caspase 
inhibitor B13R/Spi2, they exhibit markedly reduced necrotic 
activation-induced cell death (AICD) in response to anti-CD3 
antibody in comparison to wild-type T cells. Moreover, treat-
ment of wild-type T cells expressing RIP3 with a combination 
of anti-CD3, zVAD (to mimic the effects of vaccinia virus infec-
tion), and necrostatin-1 inhibits AICD. The requirement for RIP3 
in the induction of cell death in vaccina virus-infected cells sug-
gests that in vivo, the protection against vaccina virus infection 
mediated by TNF could act through RIP3-dependent necrop-
tosis. Indeed, mice lacking RIP3 have increased viral titers and 
succumb to vaccina virus infection, whereas wild-type mice do 
not (Cho et al., 2009). Necroptotic cell death likely serves two 
functions in vivo. First, it acts as a backup mechanism to kill 
virus-infected cells if the apoptotic pathway is blocked. Sec-
ond, necroptosis may promote the release of intracellular dan-
ger-associated molecular patterns, which act as endogenous 
adjuvants that boost the innate immune response.
Interestingly, the pancreatitis-inducing effects of the chemi-
cal cerulein (including pancreas acinar cell loss and necrosis) 
are largely absent in mice lacking RIP3 in comparison to their 
wild-type littermates (He et al., 2009; Zhang et al., 2009). In 
view of the role of RIP3 in metabolic regulation, it is possible 
that the primary purpose of RIP3 signaling is to increase the 
cellular energy levels to promote cell survival or repair after 
toxic insult, injury, or infection. Thus, necroptosis may be a 
byproduct of overstimulation or dysregulation of this prosur-
vival pathway, similar to the role played by excess autophagy in 
promoting cell death instead of survival.
Conclusions and Perspectives
Death receptor-induced necroptosis is a physiologically rel-
evant form of cell death that occurs in the absence of suffi-
cient caspase-8 activity. The work of Cho et al., He et al., and 
Zhang et al. indicates that the RIP1/RIP3 necrosome regulates 
the decision between necroptosis and survival. Furthermore, 
apoptosis actively prevents necroptotic signaling through the 
cleavage of RIP1 and RIP3 by caspases. Thus, apoptotic path-
ways appear to be mainly controlled by the proteolytic cas-
pase network, whereas necroptotic signaling is controlled by a 
kinase cascade. The RIP3 signaling cascade further connects 
necroptosis with energy metabolism, suggesting a role for 
necrotic cell death in metabolic diseases such as diabetes and 
obesity. The potential involvement of necroptosis in disease 
could lead to the development of kinase inhibitors (in addition 
to the necrostatins) that prevent pathological cell death result-
ing from ischemia-reperfusion injury as occurs following organ 
transplantation, cardiac infarction, stroke, or traumatic brain 
injury. The findings of Cho et al. also establish an in vivo role for 
RIP1/RIP3-mediated necroptosis in antiviral responses, sug-
gesting that inhibition of necroptosis, like inhibition of apopto-
sis, might be a strategy used by viruses to evade the immune 
system. A better understanding of alternative cell death path-
ways could also be exploited therapeutically in the treatment 232 Cell 138, July 24, 2009 ©2009 Elsevier Inc.of cancers, which often inactivate apoptotic pathways. In the 
coming years, our view of this alternative cell death pathway 
will be broadened by further identification of RIP1 and RIP3 
substrates, molecular signal transducers that lead to necrop-
tosis, and physiological and pathological conditions involving 
necroptosis.
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